Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients With Advanced Gallbladder Carcinoma or Cholangiocarcinoma

NCT01093222 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01093222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01093222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients With Advanced Gallbladder Carcinoma or Cholangiocarcinoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2010
Completion date
September 30, 2014
Enrollment
40 (actual)
Sites
141

Conditions

As the registry lists them; a condition with its own page is linked.

extrahepatic bile duct adenocarcinoma, gallbladder adenocarcinoma, gallbladder adenocarcinoma with squamous metaplasia, hilar cholangiocarcinoma, recurrent extrahepatic bile duct carcinoma, recurrent gallbladder carcinoma, undifferentiated gallbladder carcinoma, unresectable extrahepatic bile duct carcinoma, unresectable gallbladder carcinoma